Literature DB >> 11678067

Hospitalization and total medical costs for privately insured persons with schizophrenia.

W H Crown1, C Neslusan, P A Russo, S Holzer, R Ozminkowski, T Croghan.   

Abstract

This study used data from the 1991-1993 MarketScan files, a large database of private sector inpatient, outpatient, and prescription drug medical claims, to identify a sample of 665 patients with schizophrenia. Descriptive and multivariate analyses were conducted on the subsamples with hospitalizations (N = 185) and without hospitalizations (N = 480) in the 1-year period following the initial diagnosis for schizophrenia observed in the 1991-1993 time period. After controlling for patient demographic characteristics, medical co-morbidities, and other factors, the cost of hospitalization itself was found to be $15,805.

Entities:  

Mesh:

Year:  2001        PMID: 11678067     DOI: 10.1023/a:1011139215761

Source DB:  PubMed          Journal:  Adm Policy Ment Health        ISSN: 0894-587X


  9 in total

Review 1.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

2.  In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Robert Lin; Yuling Liang; Steven J Siegel
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

3.  Evaluation of a Culturally Tailored Skills Intervention for Latinos with Persistent Psychotic Disorders.

Authors:  Brent T Mausbach; Jesus Bucardo; Veronica Cardenas; Christine L McKibbin; Concepcion Barrio; Sherrill R Goldman; Dilip V Jeste; Thomas L Patterson
Journal:  Am J Psychiatr Rehabil       Date:  2008-01-01

4.  Resource utilization and cost in a commercially insured population with schizophrenia.

Authors:  Kathryn Fitch; Kosuke Iwasaki; Kathleen F Villa
Journal:  Am Health Drug Benefits       Date:  2014-01

5.  The Use of the Japanese Public Financial Support Has Positive Impact on Persistence with Outpatient Treatments for Schizophrenia: Single-center Retrospective Cohort Study in Japan.

Authors:  Masatoshi Arikawa; Kazumi Ota; Takaharu Azekawa; Shizuko Ohashi; Yoichi Funaoka; Hiroshi Yoshiie; Haruka Koshi; Yohei Takaishi; Saeka Nakao
Journal:  Patient Prefer Adherence       Date:  2021-02-02       Impact factor: 2.711

6.  The cost of schizophrenia in Japan.

Authors:  Mitsuhiro Sado; Ataru Inagaki; Akihiro Koreki; Martin Knapp; Lee Andrew Kissane; Masaru Mimura; Kimio Yoshimura
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-30       Impact factor: 2.570

7.  Predictors of repeated sick leave in the workplace because of mental disorders.

Authors:  Mitsuhiro Sado; Joichiro Shirahase; Kimio Yoshimura; Yuki Miura; Kazuhiro Yamamoto; Hajime Tabuchi; Motoichiro Kato; Masaru Mimura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-29       Impact factor: 2.570

8.  Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Authors:  José M Olivares; Jan Sermon; Michiel Hemels; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2013-10-23       Impact factor: 3.455

Review 9.  Global economic burden of schizophrenia: a systematic review.

Authors:  Huey Yi Chong; Siew Li Teoh; David Bin-Chia Wu; Surachai Kotirum; Chiun-Fang Chiou; Nathorn Chaiyakunapruk
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-16       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.